Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results

Immix Biopharma (NASDAQ:IMMX) released its earnings results on Wednesday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.12), FiscalAI reports.

Immix Biopharma Trading Down 6.5%

Shares of NASDAQ IMMX traded down $0.57 during mid-day trading on Friday, reaching $8.15. 750,582 shares of the company’s stock were exchanged, compared to its average volume of 889,094. Immix Biopharma has a twelve month low of $1.34 and a twelve month high of $11.61. The firm has a market capitalization of $431.62 million, a price-to-earnings ratio of -9.16 and a beta of 0.25. The business has a fifty day simple moving average of $7.70 and a 200 day simple moving average of $5.20.

Analyst Ratings Changes

Several brokerages have recently commented on IMMX. Mizuho initiated coverage on shares of Immix Biopharma in a research report on Monday, February 9th. They set an “outperform” rating and a $14.00 price target for the company. HC Wainwright raised their price objective on shares of Immix Biopharma from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd. Citizens Jmp restated a “market outperform” rating and set a $23.00 price objective on shares of Immix Biopharma in a report on Friday. Finally, Morgan Stanley began coverage on shares of Immix Biopharma in a research report on Wednesday. They set an “overweight” rating and a $20.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $18.00.

Institutional Trading of Immix Biopharma

Large investors have recently bought and sold shares of the business. Balyasny Asset Management L.P. acquired a new stake in Immix Biopharma during the 4th quarter worth approximately $67,000. Squarepoint Ops LLC acquired a new position in shares of Immix Biopharma in the fourth quarter valued at approximately $112,000. Quadrature Capital Ltd acquired a new position in shares of Immix Biopharma in the fourth quarter valued at approximately $116,000. Persistent Asset Partners Ltd bought a new stake in shares of Immix Biopharma during the fourth quarter worth $166,000. Finally, Hudson Bay Capital Management LP bought a new stake in shares of Immix Biopharma during the fourth quarter worth $176,000. 11.26% of the stock is owned by institutional investors.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.